Sirius Therapeutics Raises Nearly $50M in Series B2 Funding
Sirius Therapeutics, a San Diego-based company specializing in siRNA therapeutics for individuals with chronic illnesses, has recently secured nearly $50 million in Series B2 funding.
This funding round was spearheaded by an undisclosed investor, with additional contributions from BioTrack Capital, as well as existing backers such as OrbiMed, Creacion Ventures, and Hankang Capital.
The primary goal of this funding is to propel the clinical development of the company’s innovative siRNA therapeutics designed for cardiometabolic disorders. Additionally, the funds will support the advancement of new RNA delivery technologies.
Established in 2021 and under the leadership of CEO Dr. Qunsheng Ji, Sirius Therapeutics is dedicated to developing siRNA therapeutics for patients dealing with chronic conditions on a global scale. The company has set up an innovation center in the United States and a translational medicine center in China, focusing on providing solutions for the treatment and management of chronic diseases.
With this recent funding round, Sirius Therapeutics has now raised a total of nearly $150 million, showcasing significant support and interest in its groundbreaking approach to addressing chronic illnesses.
For more information about Sirius Therapeutics and its innovative therapies, visit their official website.
FinSMEs
10/05/2025
